Peptone raises $40m in Series A funding to advance its protein analysis platform
The round was led by F-Prime Capital to support the development of novel therapeutics for disordered proteins.
≈ £32.0M at $1 = £0.8005 on 9 Jun 2022
Peptone is a molecular computational physics company that applies advanced biophysics, atomic-level experiments, and machine learning to drug discovery.
Peptone has secured $40m in a Series A funding round led by F-Prime Capital. The round included participation from Bessemer Venture Partners, Walden Catalyst Ventures, Hoxton Ventures, and dRX Capital.
The capital will be used to build a new research facility in Switzerland, support the company algorithmic engine, and advance its drug discovery platform targeting disordered proteins involved in diseases such as cancer and diabetes.
The London-based biotech firm combines nuclear magnetic resonance spectroscopy, hydrogen-exchange mass spectrometry, machine learning, and supercomputing to model intrinsically disordered proteins that traditional drug discovery methods fail to target.
From the founder
"By taking a rigorous and computer-driven experimental physics approach to analysing proteins, we can go beyond classical drug discovery approaches and observe protein behaviour that algorithms like AlphaFold cannot. This new funding will allow us to further advance our platform and support the investigation of the disordered protein universe towards developing drugs of the future,"
Kamil Tamiola
Co-founder and CEO at Peptone
Investor perspective
"Disordered proteins are important in biology but lack a constant binding pocket. Peptone’s platform exploits the accuracy of experimental techniques with the efficiency of in silico modelling to unlock these targets,"
Alex Pasteur
Partner, F-Prime Capital
Use of funds
- 01Fund research and development
- 02Build out infrastructure
